Imaging brain tumors with ferumoxtran-10, a nanoparticle magnetic resonance contrast agent

Therapy

Volumn 2, Issue 6, 2005, Pages 871-882

  Murillo, Tulio P ^a   Sandquist, Chloe ^b   Jacobs, Paula M ^c   Nesbit, Gary ^b   Manninger, Sandor ^b   Neuwelt, Edward A ^b  

^a Department of Neurosurgery   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Advanced Magnetics Inc   (United States)

Author keywords

Ferumoxtran 10; Glioma; Inflammation; Magnetic resonance contrast agents; Metastatic brain tumors; Ultrasmall superparamagnetic iron oxide

Indexed keywords

GADODIAMIDE; GADOLINIUM PENTETATE; NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADULT; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN SCINTISCANNING; CANCER CLASSIFICATION; CANCER INFILTRATION; CANCER STAGING; CELL INFILTRATION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DEMOGRAPHY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG HALF LIFE; DRUG INFUSION; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; IMAGE DISPLAY; IMAGE QUALITY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING;

EID: 28344456922     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.1586/14750708.2.6.871     Document Type: Article

References (47)

1. Jung C, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, and ferumoxsil. Magn. Reson. Imaging 13, 661-674 (1995).
2. Ros PR, Freeny PC, Harms SE et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196, 481-488 (1995).
3. Hoffman HT, Quets J, Toshiaki T et al. Functional magnetic resonance imaging using iron oxide particles in characterizing head and neck adenopathy. Laryngoscope 110, 1425-1430 (2000).
4. Anzai Y, Piccoli CW, Outwater EK et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: Phase III safety and efficacy study. Radiology 228(3), 777-788 (2003).
5. Ersoy H, Jacobs P, Kent CK, Prince MR. Blood pool MR angiography of aortic stent-graft endoleak. Am. J. Roentgenol. 182, 1181-1186 (2004).
6. Prince MR, Zhang HL, Chabra SG, Jacobs P, Wang Y. A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. J. X-Ray Science Technology 11, 231-240 (2003).
7. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J. Magn. Reson. Imaging 9, 228-232 (1999).
8. Varallyay P, Nesbit G, Muldoon LL et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. Am. J. Neuroradiol. 23(4), 510-519 (2002).
9. Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC, Enochs WS. MR imaging of phagocytosis in experimental gliomas. Radiology 197, 3533-3538 (1995).
10. Neuwelt EA, Weissleder R, Nilaver G et al. Delivery of virus-sized iron oxide particles to rodent CNS neurons. Neurosurgery 34, 777-784 (1994).
11. Muldoon LL, Pagel MA, Kroll RA, Roman-Goldstein S, Jones RS, Neuwelt EA. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery. Am. J. Neuroradiol. 20(2), 217-222 (1999).
12. Muldoon LL, Manninger S, Pinkston KE, Neuwelt EA. Imaging, distribution and toxicity of superparamagnetic iron oxide magnetic resonance agents in rat brain and intracerebral tumor. Neurosurgery (2005) (In Press).
13. Moore A, Marecos E, Bogdanov A Jr, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 214(2), 568-574 (2000).
14. Egelhof T, Delbeck N, Hartmann M et al. Can superparamagnetic contrast media improve MRI-tomographic images of experimental gliomas? Radiologe 38(11), 943-947 (1998).
15. Hunt MA, Bago AG, Neuwelt EA Single-dose contrast agent for intraoperative mr imaging of intrinsic brain tumors using ferumoxtran-10. Am. J. Neuroradiology 26(5), 1084-1088 (2005).
16. Neuwelt EA, Varallyay P, Bago AG, Muldoon LL, Nesbit G, Nixon R. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumors. Neuropath. Applied Neurobiol. 30, 456-471 (2004).
17. Nguyen BC, Stanford W, Thompson BH et al. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma. J. Magn. Reson. Imaging 10, 468-473 (1999).
18. Taylor AM, Panting JR, Keegan J et al. Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography. J. Magn. Reson. Imaging 9, 220-227 (1999).
19. Anzai Y, Prince MR, Chenevert TL et al. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J. Magn. Reson. Imaging 7, 209-214 (1997).
20. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications: a review. J. Drug Target 6, 167-174 (1998).
21. Corot C, Petry KG, Trivedi R et al. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest. Radiol. 39, 619-625 (2004).
22. Dousset V, Delalande C, Ballarino L et al. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn. Reson. Med. 41(2), 329-333 (1999).
23. Xu S, Jordan Ek, Brocke S et al. Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION-46L enhanced in vivo MRI: early histopathological correlation. J. Neurosci. Res. 52, 549-558 (1998).
24. Manninger SP, Muldoon LL, Nesbit G, Murillo T, Jacobs PM, Neuwelt EA. An exploratory study of ferumoxtran-10 as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. Am. J. Neuroradiology (2005) (In Press).
25. McLachlan SJ, Morris MR, Lucas MA et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J. Magn. Reson. Imaging 4(3), 301-307 (1994).
26. Arbab AS, Yocum GT, Kalish H et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 104(4), 1217-1223 (2004).
27. Kamiryo T, Lopes MB, Kassell NF, Steiner L, Lee KS. Radiosurgery-induced microvascular alterations precede necrosis of the brain neuropil. Neurosurgery 49(2), 409-414 (2001).
28. Uematsu Y, Fujita K, Tanaka Y et al. Gamma knife radiosurgery for neuroepithelial tumors: radiological and histological changes. Neuropathology 21(4), 298-306 (2001).
29. Griem ML, Robotewskyj A, Nagel RH. Potential vascular damage from radiation in the space environment. Adv. Space Res. 14(10), 555-563 (1994).
30. Silbergeld DL, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J. Neurosurg. 86(3), 525-531 (1997).
31. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57(7), 1248-1252 (2001).
32. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 180(2), 467-474 (1991).
33. Doerfler A, Engelhorn T, Heiland S, Knauth M, Wanke I, Forsting M. MR contrast agents in acute experimental cerebral ischaemia: potential adverse impacts on neurologic outcome and infarction size. J. Magn. Reson. Imaging 11(4), 418-424 (2000).
34. Haraldseth O, Jones RA, Muller TB, Fahlvik AK, Oksendal AN. Comparison of dysprosium DTPA BMA and superparamagnetic iron oxide particles as susceptibility contrast agents for perfusion imaging of regional cerebral ischaemia in the rat. J. Magn. Reson. Imaging 6(5), 714-717 (1996).
35. Brex PA, O'Riordan JI, Miszkiel KA et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 53(6), 1184-1190 (1999).
36. Clifford DB, Gado MH, Levy BK. Osmotic demyelination syndrome. Lack of pathologic and radiologic imaging correlation. Arch. Neurol. 46(3), 343-347 (1989).
37. Iizuka T, Sakai F, Kan S, Suzuki N. Slowly progressive spread of the stroke-like lesions in MELAS. Neurology 61(9), 1238-1244 (2003).
38. Yapici Z, Eraksoy M. Bilateral demyelinating tumefactive lesions in three children with hemiparesis. J. Child. Neurol. 17(9), 655-660 (2002).
39. Butteriss DJ, Ismail A, Ellison DW, Birchall D. Use of serial proton magnetic resonance spectroscopy to differentiate low grade glioma from tumefactive plaque in a patient with multiple sclerosis. Br. J. Radiol. 76(909), 662-665 (2003).
40. Galanaud D, Nicoli F, Le Fur Y et al. Multimodal magnetic resonance imaging of the central nervous system. Biochimie 85(9), 905-914 (2003).
41. De Groot CJ, Bergers E, Kamphorst W et al. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and reactive lesions. Brain 124(Pt 8), 1635-1645 (2001).
42. Nathoo N, Barnett GH, Golubic M. The eicosanoid cascade: possible role in gliomas and meningiomas. J. Clin. Pathol. 57(1), 6-13 (2004).
43. Jackson RJ, Fuller GN, Abi-Said D et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neurooncology 3(3), 193-200 (2001).
44. Rausch M, Hiestand P, Baumann D, Canner C, Rudin M. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn. Reson. Med. 50(2), 309-314 (2003).
45. Dousset V, Ballarino L, Delalande C et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. Am. J. Neuroradiol. 20(2), 223-227 (1999).
46. Frank JA, Miller BR, Arbab AS et al. Clinically applicable labeling of mammalian cells and stem cells by combining (FDA)-approved superparamagnetic iron oxides and commonly available transfection agents. Radiology 228, 480-487 (2003).
47. Arbab AS, Bashaw LA, Miller BR et al. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology 229, 838-846 (2003).